Indivior Management

Management Kriterienprüfungen 3/4

Indivior CEO ist Mark Crossley , ernannt in Jun 2020, hat eine Amtszeit von 4.42 Jahren. Die jährliche Gesamtvergütung beträgt $7.57M , bestehend aus 11% Gehalt und 89% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.077% der Aktien des Unternehmens, im Wert von £843.36K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.4 Jahre bzw. 3.7 Jahre.

Wichtige Informationen

Mark Crossley

Geschäftsführender

US$7.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	11.0%
Amtszeit als Geschäftsführer	4.4yrs
Eigentum des Geschäftsführers	0.08%
Durchschnittliche Amtszeit des Managements	4.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.7yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mark Crossley im Vergleich zu den Einnahmen von Indivior verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$141m
Mar 31 2024	n/a	n/a	US$5m
Dec 31 2023	US$8m	US$834k	US$2m
Sep 30 2023	n/a	n/a	-US$235m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	n/a	n/a	-US$50m
Dec 31 2022	US$11m	US$806k	-US$53m
Sep 30 2022	n/a	n/a	US$166m
Jun 30 2022	n/a	n/a	US$152m
Mar 31 2022	n/a	n/a	US$166m
Dec 31 2021	US$5m	US$775k	US$205m
Sep 30 2021	n/a	n/a	US$156m
Jun 30 2021	n/a	n/a	US$139m
Mar 31 2021	n/a	n/a	US$95m
Dec 31 2020	US$761k	US$675k	-US$148m
Sep 30 2020	n/a	n/a	-US$190m
Jun 30 2020	n/a	n/a	-US$152m
Mar 31 2020	n/a	n/a	-US$95m
Dec 31 2019	US$1m	US$528k	US$134m
Sep 30 2019	n/a	n/a	US$213m
Jun 30 2019	n/a	n/a	US$254m
Mar 31 2019	n/a	n/a	US$248m
Dec 31 2018	US$551k	US$494k	US$275m
Sep 30 2018	n/a	n/a	US$106m
Jun 30 2018	n/a	n/a	US$67m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$2m	US$413k	US$58m

Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD7.57M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD2.22M).

Entschädigung vs. Einkommen: MarkDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Mark Crossley

4.4yrs

Amtszeit

US$7,574,600

Vergütung

Mr. Mark Crossley has been Chief Executive Officer of Indivior PLC since June 29, 2020 and served as its Chief Financial and Operations Officer since July 29, 2019 until June 29, 2020. He has a wealth of f...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mark Crossley	CEO & Executive Director	4.4yrs	US$7.57m	0.077% £ 843.4k
Ryan Preblick	CFO & Executive Director	4.4yrs	US$4.86m	0.051% £ 556.7k
Christian Heidbreder	Chief Scientific Officer	no data	keine Daten	0.073% £ 802.4k
Jason Thompson	Vice President of Investor Relations	no data	keine Daten	keine Daten
Cynthia Cetani	Chief Integrity & Compliance Officer	6.1yrs	keine Daten	0.15% £ 1.6m
Jeffrey Burris	Chief Legal Officer	2.9yrs	keine Daten	0.00060% £ 6.6k
Richard Simkin	Chief Commercial Officer	no data	keine Daten	0.092% £ 1.0m
Jon Fogle	Chief Human Resources Officer	less than a year	keine Daten	0.047% £ 521.1k
Hillel West	Chief Manufacturing & Supply Officer	4.8yrs	keine Daten	0.096% £ 1.1m
Vishal Kalia	SVP of US Treatment Access	no data	keine Daten	0.10% £ 1.1m
Angela Colon-Mahoney	Chief Human Resources Officer	less than a year	keine Daten	keine Daten
Kathryn Hudson	Company Secretary	9.4yrs	keine Daten	0.046% £ 504.2k

4.4yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: INDVLDas Führungsteam des Unternehmens gilt als erfahren (4.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mark Crossley	CEO & Executive Director	7.8yrs	US$7.57m	0.077% £ 843.4k
Ryan Preblick	CFO & Executive Director	4yrs	US$4.86m	0.051% £ 556.7k
Graham Hetherington	Independent Chairman	5yrs	US$357.97k	0.017% £ 187.0k
Juliet Thompson	Senior Independent Director	3.7yrs	US$121.62k	0.0030% £ 33.3k
Peter James Bains	Independent Non-Executive Director	5.3yrs	US$115.12k	0.0085% £ 93.2k
Barbara Ryan	Independent Non-Executive Director	2.4yrs	US$121.00k	keine Daten
Mark Stejbach	Independent Non-Executive Director	3.7yrs	US$125.10k	0.011% £ 120.2k
David Wheadon	Independent Non-Executive Director	less than a year	keine Daten	keine Daten
Jerome Lande	Non-Executive Director	3.7yrs	US$103.00k	0.000050% £ 548.9
Joanna Le Couilliard	Independent Non-Executive Director	3.7yrs	US$104.92k	0.0012% £ 12.8k
Keith Humphreys	Independent Non-Executive Director	less than a year	US$17.80k	0.0019% £ 20.5k

3.7yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: INDVLDie Vorstandsmitglieder gelten als erfahren (3.7 Jahre durchschnittliche Amtszeit).

Indivior Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Jerome Lande to Step Down from the Board of Indivior plc

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Announces Board Committee Changes

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Chief Human Resources Officer recently sold UK£1.8m worth of stock

Recent updates

Indivior PLC Shares Results from a Randomized, Open-Label Sub-Study in Opioid-Dependent Participants Seeking Treatment

Jerome Lande to Step Down from the Board of Indivior plc

Oaktree Capital Sends a Letter to Indivior PLC

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings released: EPS: US$0.35 (vs US$0.32 in 1Q 2023)

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

New minor risk - Insider selling

Chief Human Resources Officer recently sold UK£1.8m worth of stock

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

New minor risk - Share price stability

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC Revises Earnings Guidance for the Year 2023

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

High number of new directors

Full year 2022 earnings released: US$0.38 loss per share (vs US$1.41 profit in FY 2021)

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior plc Announces Executive Changes

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Investor sentiment deteriorated over the past week

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder

First quarter 2022 earnings released: EPS: US$0.06 (vs US$0.11 in 1Q 2021)

Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022

High number of new directors

Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC

Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

Indivior PLC, Annual General Meeting, May 05, 2022